DEF 14A

Company

Spyre Therapeutics, Inc.

Filed

April 1, 2024

Period of Report

May 13, 2024

Accession Number

0001636282-24-000021

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →